{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:21:46Z","timestamp":1780489306950,"version":"3.54.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) exacerbations require accurate severity assessment for optimal management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study investigated serum cystatin C as a potential biomarker for evaluating acute exacerbations of COPD (AECOPD) severity and its correlation with established clinical assessment tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study enrolled 389 consecutive AECOPD patients hospitalized from 01 January 2024 to 31 December 2025. Patient demographics, laboratory parameters, arterial blood gases, CAT scores, mMRC grading, and GOLD staging were collected. Statistical analyses included Spearman correlation, ANOVA, multiple regression, ROC curve analysis, and restricted cubic spline modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients averaged 68.71 \u00b1 0.8 years with 71.7% male pre-dominance. Cystatin C levels progressively increased across CAT score severity groups: mild (&amp;lt; 10 points) 1.080 \u00b1 0.32 mg\/L, moderate (10\u201320) 1.380 \u00b1 0.41 mg\/L, severe (21\u201330) 1.720 \u00b1 0.52 mg\/L, and very severe (&amp;gt;30) 2.150 \u00b1 0.68 mg\/L (\n                      <jats:italic>F<\/jats:italic>\n                      = 78.42,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Strong positive correlations existed between cystatin C and CAT scores (\n                      <jats:italic>rs<\/jats:italic>\n                      = 0.687), mMRC grading (\n                      <jats:italic>rs<\/jats:italic>\n                      = 0.612), and GOLD staging (\n                      <jats:italic>rs<\/jats:italic>\n                      = 0.534, all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Multiple regression confirmed cystatin C as an independent CAT score predictor (\u03b2 = 5.89, 95%CI: 4.72\u20137.06,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). For severe AECOPD prediction (CAT \u2265 21), cystatin C demonstrated good diagnostic performance with AUC 0.847 (95%CI: 0.807\u20130.887), optimal cutoff 1.52 mg\/L, sensitivity 81.5%, and specificity 78.2%. Restricted cubic spline analysis revealed a significant non-linear dose-response relationship (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.023).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum cystatin C strongly correlates with AECOPD severity across multiple assessment scales and demonstrates good diagnostic accuracy, supporting its potential as a reliable biomarker for clinical severity evaluation in COPD exacerbations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1804455","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T05:20:30Z","timestamp":1775712030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of cystatin C as a biomarker for AECOPD severity: a cross-sectional study integrating CAT score, mMRC grade, and GOLD stage"],"prefix":"10.3389","volume":"13","author":[{"given":"Haoran","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Fuyang Women's and Children's Hospital, Fuyang","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengwen","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Fuyang Women's and Children's Hospital, Fuyang","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Fuyang Women's and Children's Hospital, Fuyang","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Fuyang Women's and Children's Hospital, Fuyang","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"8","author":"GBD","year":"2020","journal-title":"Lancet Res Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet (London, England)."},{"key":"B3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax."},{"key":"B4","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD assessment test","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thx.54.7.581","article-title":"Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease","volume":"54","author":"Bestall","year":"1999","journal-title":"Thorax."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2300239","DOI":"10.1183\/13993003.00239-2023","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"61","author":"Agust\u00ed","year":"2023","journal-title":"Eur Res J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1042\/bj2680287","article-title":"Structure and expression of the human cystatin C gene","volume":"268","author":"Abrahamson","year":"1990","journal-title":"Biochem J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","article-title":"Update on cystatin C: incorporation into clinical practice","volume":"62","author":"Shlipak","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"Knight","year":"2004","journal-title":"Kidney Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e040050","DOI":"10.1161\/JAHA.124.040050","article-title":"Association between the serum creatinine to cystatin C ratio and cardiovascular disease in middle-aged and older adults in China: a nationwide cohort study","volume":"14","author":"Chen","year":"2025","journal-title":"J Am Heart Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1515\/CCLM.2008.336","article-title":"Cystatin C: current position and future prospects","volume":"46","author":"S\u00e9ronie-Vivien","year":"2008","journal-title":"Clin Chemand Lab Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2147\/COPD.S80673","article-title":"Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels","volume":"10","author":"Yoshizawa","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.clnu.2020.08.010","article-title":"Serum creatinine\/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease","volume":"40","author":"Hirai","year":"2021","journal-title":"Clin Nutr. (Edinburgh, Scotland)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.5_suppl_2.398S","article-title":"Toward a consensus definition for COPD exacerbations","author":"Rodriguez-Roisin","year":"2000","journal-title":"Chest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e18743064279064","DOI":"10.2174\/0118743064279064231227070344","article-title":"Global initiative for chronic obstructive lung disease (GOLD) 2023 guidelines reviewed","volume":"18","author":"Sharma","year":"2024","journal-title":"Open Respir Med J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(18)30841-9","article-title":"Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary health [CPH] study): a national cross-sectional study","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet (London, England)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.5588\/ijtld.19.0397","article-title":"The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries","volume":"23","author":"Halpin","year":"2019","journal-title":"Int J Tuberc Lung Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","article-title":"Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype","volume":"7","author":"Agust\u00ed","year":"2012","journal-title":"PLoS ONE."},{"key":"B19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1164\/rccm.201209-1665OC","article-title":"Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease","volume":"187","author":"Vanfleteren","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1214234","article-title":"Cystatin C versus creatinine in determining risk based on kidney function","volume":"369","author":"Shlipak","year":"2013","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1378\/chest.128.2.518","article-title":"In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study","volume":"128","author":"Ai-Ping","year":"2005","journal-title":"Chest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ajem.2017.08.014","article-title":"Prevalence and predictors associated with severe pulmonary hypertension in COPD","volume":"36","author":"Samareh Fekri","year":"2018","journal-title":"Am J Emerg Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1164\/rccm.1991P1","article-title":"Chronic obstructive pulmonary disease (COPD)","volume":"199","author":"Lareau","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40520-013-0150-6","article-title":"Serum cystatin C and indices of lung function in elderly Chinese men with chronic obstructive pulmonary disease","volume":"26","author":"Zhang","year":"2014","journal-title":"Aging Clin Exp Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.200605-713OC","article-title":"C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease","volume":"175","author":"Dahl","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/thoraxjnl-2012-201871","article-title":"Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease","volume":"68","author":"Duvoix","year":"2013","journal-title":"Thorax."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1001\/jama.2013.5732","article-title":"Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease","volume":"309","author":"Thomsen","year":"2013","journal-title":"Jama."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/sim.3841","article-title":"Dose-response analyses using restricted cubic spline functions in public health research","volume":"29","author":"Desquilbet","year":"2010","journal-title":"Stat Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim Biophys Acta."},{"key":"B31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1378\/chest.09-1710","article-title":"Chronic renal failure: a neglected comorbidity of COPD","volume":"137","author":"Incalzi","year":"2010","journal-title":"Chest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"25855","DOI":"10.1038\/srep25855","article-title":"Chronic obstructive pulmonary disease is associated with risk of chronic kidney disease: a nationwide case-cohort study","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1084\/jem.166.6.1912","article-title":"Constitutive secretion of cystatin C (gamma-trace) by monocytes and macrophages and its downregulation after stimulation","volume":"166","author":"Warfel","year":"1987","journal-title":"J Exp Med."}],"updated-by":[{"DOI":"10.3389\/fmed.2026.1884988","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1804455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:23:46Z","timestamp":1780482226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1804455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1804455"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1804455","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"article-number":"1804455"}}